Insider Cluster (6 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago
Insider cluster: 6 insiders, $0.0M total
Actionable Insight • Neutral

The insider sales are too small to be informative. Focus on the $400M shelf registration and going-concern risk: KPTI must raise capital by late Q3 2026, which will likely cause severe dilution. Monitor for any ATM debuts or equity offering announcements.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
KPTI ▼ -71.57% at T+60d
NEUTRAL call ✗ call lost -71.57% · α vs SPY -76.42% · entry $7.14 → $2.03
Entry anchored
May 15, 03:59 PM ET
via exchange tick
T+1d
+4.62%
call +4.62% · α +5.27%
$7.47
settled 5mo ago
T+5d
+25.63%
call +25.63% · α +24.01%
$8.97
settled 4mo ago
T+20d
+27.45%
call +27.45% · α +25.87%
$9.10
settled 4mo ago
T+60d
-71.57%
call -71.57% · α -76.42%
$2.03
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the same day as the Q1 earnings release. The sales are minimal in size (0.019% of market cap) and likely routine post-earnings transactions. Three directors received non-cash stock grants on May 21. The sales do not signal bearish sentiment given their trivial value, but the company faces significant going-concern risk and potential dilution from a $400M shelf registration.

Key Financial Metrics

Direction
selling
Total Value
$35.0K
Insiders
6

Key Facts

  • Six C-suite insiders sold a total of $35K in shares on May 14, 2026, all at $9.50/share.
  • Three directors received grants of 15,508 shares each on May 21, 2026, at $0 (non-cash).
  • Total insider sales represent 0.019% of KPTI's $185M market cap — well below materiality threshold.
  • Q1 2026 revenue was $35.1M (up 17% YoY), net loss $22.4M, beat consensus EPS of -$1.44 by 29%.
  • Phase 3 SENTRY myelofibrosis trial missed second co-primary endpoint; $400M shelf registration filed.
  • Cash runway extends only into late Q3 2026, creating acute financing risk.

Financial Impact

Insider sales of $35K are immaterial; the shelf registration of $400M (216% of market cap) is the key risk.

dilutioncash runway

Risk Factors

  • Potential massive dilution from the $400M shelf registration relative to $185M market cap.
  • Going concern with cash runway only to late Q3 2026.
  • Phase 3 SENTRY trial failure limits pipeline upside.
  • Insider sales, while small, occur amid high uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1779826471396
17 reports for KPTI
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+60▲ +71.57%May 15, 2026
Filters
Rows
Reports for KPTI — sortable, filterable
TypeNow
Sep 11, 2026
21d ago
8-K
BEARISH ★ 9/10
$1.61 $1.88▼ −16.77%▼ −16.99%$0.8050 (+50.00%)
Aug 31, 2026
4w ago
8-K
BULLISH ★ 6/10
$2.06 $1.72▼ −16.50%▼ −16.36%$0.8050 (−60.92%)
Aug 13, 2026
7w ago
8-K
BEARISH ★ 8/10
$1.99 $1.82▲ +8.54%▲ +6.58%$0.8050 (+59.55%)
Aug 10, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$1.96 $1.81▼ −7.65%▼ −7.61%$0.8050 (−58.93%)
Jul 31, 2026
9w ago
8-K
MIXED ★ 6/10
$1.92 $2.12▲ +10.42%▲ +6.91%$0.8050 (−58.07%)
Jul 17, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$7.47 $7.41▼ −0.80%▼ −0.38%$0.8050 (−89.22%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.14 $8.97▲ +25.63%▲ +24.01%$0.8050 (−88.73%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.14 $8.97▲ +25.63%▲ +24.01%$0.8050 (−88.73%)
May 15, 2026
19w ago
Insider Cluster
BEARISH ★ 6/10
$7.14 $8.97▼ −25.63%▼ −24.01%$0.8050 (+88.73%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.14 $8.97▲ +25.63%▲ +24.01%$0.8050 (−88.73%)
Showing 10 of 17

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 26, 2026